Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Wakunaga Signs an MTA with A-CUBE for Therapeutic MABs
January 10, 2011
- Velcade Approved for Naive MM Patients
January 10, 2011
- DSP, Chugai to Jointly Develop MDS Vaccine
January 10, 2011
- Kyorin Refuses Sawai Further Explanations
January 10, 2011
- Lunabell Approved for Functional Dysmenorrhea
January 10, 2011
- Takeda Signs Anti-Obesity Drug Discovery Partnership Agreement
January 10, 2011
- ViiV Reduces Operation Costs Utilizing GSK's Business Resources
January 10, 2011
- Daiichi Sankyo's Sevikar HCT Approved in Germany
January 10, 2011
- Fulvestrant Better Controls Breast Cancer than Anastrozole: AZ
January 10, 2011
- RG1678 Improves Negative Symptoms of Schizophrenia: Roche
January 3, 2011
- Sawai Asks Kyorin to Explain Why It Turned Down Merger Proposal
January 3, 2011
- Tasigna More Effective Than Glivec: Novartis
January 3, 2011
- Eli Lilly to Differentiate Byetta from Victoza
January 3, 2011
- Novartis' Zometa PIII Data Published in Lancet
January 3, 2011
- Rivaroxaban Peak Sales Expected to Exceed 2 Bil. Euro: Bayer
January 3, 2011
- Seattle Genetics, Millennium Present Positive PII Data on SGN-35 in Hodgkin's Lymphoma
January 3, 2011
- Inavir Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
January 3, 2011
- Abbott Japan Starts Business Integration with Solvay
January 3, 2011
- Millennium, Seattle Genetics Report Favorable PII Results for Brentuximab in ALCL
January 3, 2011
- Novartis to Acquire Alcon
January 3, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…